Search alternatives:
changes decrease » change increases (Expand Search), larger decrease (Expand Search), largest decrease (Expand Search)
point decrease » point increase (Expand Search)
changes decrease » change increases (Expand Search), larger decrease (Expand Search), largest decrease (Expand Search)
point decrease » point increase (Expand Search)
-
8781
DataSheet7_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.ZIP
Published 2022“…<p>Primary hyperoxaluria type I (PH1) is caused by AGXT gene mutations that decrease the functional activity of alanine:glyoxylate aminotransferase. …”
-
8782
DataSheet6_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.ZIP
Published 2022“…<p>Primary hyperoxaluria type I (PH1) is caused by AGXT gene mutations that decrease the functional activity of alanine:glyoxylate aminotransferase. …”
-
8783
DataSheet4_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.ZIP
Published 2022“…<p>Primary hyperoxaluria type I (PH1) is caused by AGXT gene mutations that decrease the functional activity of alanine:glyoxylate aminotransferase. …”
-
8784
DataSheet5_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.ZIP
Published 2022“…<p>Primary hyperoxaluria type I (PH1) is caused by AGXT gene mutations that decrease the functional activity of alanine:glyoxylate aminotransferase. …”
-
8785
DataSheet1_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.PDF
Published 2022“…<p>Primary hyperoxaluria type I (PH1) is caused by AGXT gene mutations that decrease the functional activity of alanine:glyoxylate aminotransferase. …”
-
8786
DataSheet3_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.ZIP
Published 2022“…<p>Primary hyperoxaluria type I (PH1) is caused by AGXT gene mutations that decrease the functional activity of alanine:glyoxylate aminotransferase. …”
-
8787
DataSheet2_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.ZIP
Published 2022“…<p>Primary hyperoxaluria type I (PH1) is caused by AGXT gene mutations that decrease the functional activity of alanine:glyoxylate aminotransferase. …”
-
8788
Tendency chart of monthly FVC mean.
Published 2024“…The degradation and improvement are primarily slight. The most significant improvement in monthly FVC occurs in March-April, with a predominant type of significant improvement in FVC changes. …”
-
8789
-
8790
Temperature-Responsive Peptide–Nucleotide Coacervates
Published 2021“…We derive a simple relation between the temperature and salt concentration at the critical point based on a mean-field model of phase separation. …”
-
8791
Temperature-Responsive Peptide–Nucleotide Coacervates
Published 2021“…We derive a simple relation between the temperature and salt concentration at the critical point based on a mean-field model of phase separation. …”
-
8792
-
8793
-
8794
-
8795
-
8796
-
8797
-
8798
-
8799
-
8800
Organometallic Synthesis of 2,3,6,7-Tetrasubstituted 1,8-Bis(dimethylamino)naphthalenes for Investigation of the Double Buttressing Effect in Proton Sponges
Published 2022“…Using X-ray diffraction and basicity measurements, we showed that due to the high conformational mobility of the methoxy groups, the most striking manifestations of double BE are the strong planarization of <i>peri</i>-NMe<sub>2</sub> groups and a significant decrease in basicity, while the length and the other properties of the intramolecular NHN hydrogen bond in the corresponding protonated species undergo minor changes.…”